KPP Advisory Services LLC Reduces Stock Position in Johnson & Johnson $JNJ

KPP Advisory Services LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,293 shares of the company’s stock after selling 164 shares during the period. KPP Advisory Services LLC’s holdings in Johnson & Johnson were worth $2,030,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC bought a new position in Johnson & Johnson in the 1st quarter worth about $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson during the first quarter valued at about $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $192.31 on Friday. The firm has a 50 day moving average price of $181.99 and a 200-day moving average price of $165.84. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The firm has a market capitalization of $463.15 billion, a price-to-earnings ratio of 18.56, a PEG ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion during the quarter. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JNJ. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. Finally, HSBC raised their target price on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.